Latest News
Another disease-modifying Alzheimer's therapy hits the market.
On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.
In This Issue:
- President’s Corner
- Exercise-Induced Hormone Could Treat Alzheimer’s Disease
- Researcher Spotlight: Ariel Gilad, PhD
- Tips for Managing Caregiver Stress
- Zoom In on Dementia & Alzheimer’s
- Help Fight Alzheimer’s Through a Will or Bequest
In response to overwhelming interest in its first six episodes, four additional episodes of Zoom In on Dementia & Alzheimer’s will walk participants through specific Alzheimer’s clinical trials and research studies.
BrightFocus Foundation hosted its inaugural Concert for Cures on Wednesday, June 26, at City Winery in Nashville.
A new BrightFocus-funded glaucoma vision research study suggests that Black and Asian people receive a critical glaucoma screening test less frequently than others, which could delay sight-saving treatment.
A new BrightFocus-funded study found that identifying disruptive sleep patterns may help identify people at risk of Alzheimer’s disease up to seven years prior to end of life.
A new BrightFocus study is revolutionizing our understanding of the eye through research on choroidal blood flow, potentially unlocking future treatments for macular degeneration.
Global brain and vision research nonprofit BrightFocus Foundation has appointed Dr. Adam Myers as a new member of its board of directors.
Global brain and vision research nonprofit BrightFocus Foundation and the Helen Keller Foundation for Research and Education have named ophthalmologist José Cunha-Vaz, MD, PhD, the recipient of the 2024 Helen Keller Prize for Vision Research in recognition of his immense contributions to the field.
